Skip to content 
The EBOO therapy research base is genuinely limited, and honest sources say so. The direct clinical evidence consists mainly of a single small randomized trial of 28 patients with peripheral artery disease (Di Paolo et al., 2005), an earlier uncontrolled case series (Di Paolo et al., 2000), and laboratory work on how ozone affects blood.
A 2026 umbrella review of ozone therapy overall found that it did not consistently outperform placebo across the conditions studied (Cacciatore et al., 2026). EBOO is not FDA-approved. This page lays out every real study, what each one actually showed, and where the evidence gaps are, without inventing trials that do not exist.
If you want the plain-language basics of the procedure first, see our overview of EBOO therapy. What follows is the honest state of the evidence, which is thinner than most marketing suggests, cited so you can check it yourself.
Rather than vague claims that “studies show” benefits, here is the actual EBOO therapy research- every real study- in order. It is a short list, and that honesty is the point.
Most EBOO therapy research traces back to one place. A research group in Siena, led by Nicola Di Paolo and Velio Bocci, developed EBOO in Italy around 1990. The most important clinical evidence is their 2005 randomized controlled trial, published in the International Journal of Artificial Organs. Twenty-eight patients with peripheral artery disease received either EBOO or intravenous prostacyclin. The EBOO group showed significantly greater regression of skin lesions, along with differences in pain, itching, leg heaviness, and general well-being.
This is real, peer-reviewed evidence, and it is worth taking seriously. It is also worth reading precisely: 28 patients is a small study; it covered one condition (peripheral artery disease, not chronic fatigue, autoimmune disease, or “detox”), and two decades later, an independent group has not replicated it at scale. A promising single trial is exactly that: promising and single.
Before the controlled trial, the same group published a 2000 preliminary report describing the technique after in-vitro work, animal work, and an early uncontrolled human series. Being an uncontrolled series, it can suggest safety and possible effects, but it cannot establish that EBOO caused an outcome, because there was no comparison group.
Alongside the clinical work, laboratory research measured what actually happens to blood during a session.
A frequently cited finding is a 4 to 5-fold increase in oxidative-stress markers (thiobarbituric acid reactants) after EBOO, with a proportional decrease in plasma protein thiols and, importantly, without appreciable red-cell rupture (Bocci and Di Paolo, 2005). This supports the idea that something biologically real is happening. It does not establish that the something helps any particular condition.
The most important recent piece of evidence is not about EBOO specifically, but it matters. A 2026 umbrella review of systematic reviews and randomized trials of ozone therapy (Cacciatore et al.) found that, across the conditions studied, ozone therapy did not consistently outperform placebo or standard care, and it described the overall certainty of evidence as low.
Notably, that review excluded EBOO-specific trials, because there is not a body of them to include. So the honest summary is: the broad ozone-therapy literature is larger but unconvincing, and the EBOO-specific literature is small and early. Neither supports the sweeping claims common in marketing.
EBOO has a coherent proposed mechanism, which is part of why it is scientifically interesting. Low-dose ozone acts as a mild, controlled oxidative signal, a small stress that prompts the body to upregulate its own antioxidant defenses. Mechanistic research supports the Nrf2 antioxidant pathway’s role in this response (Galie et al., 2019). The theory is often called hormesis: a small challenge producing an adaptive benefit.
Here is the crucial distinction that separates honest sources from marketing. A plausible, laboratory-supported mechanism is not proof of clinical benefit. Many interventions with elegant mechanisms fail to help patients when tested properly. The mechanism tells you EBOO is worth studying, and it also bears on whether EBOO therapy is safe, which we cover separately. Only large, controlled trials could tell you it works, and those have not been done.
Being straight about this is part of honest information. Several widely shared claims about EBOO therapy research are simply not real, and it is worth naming them so you can recognize them.
If a page cites impressive numbers without naming the study, the year, and the sample size, treat those numbers as marketing until proven otherwise. Real evidence can always be traced to a real citation, which is exactly why it helps to know the common EBOO therapy myths before you read any clinic’s research page.
An honest summary of EBOO therapy research includes its own gaps. For EBOO, the open questions are large: there are no large multi-center randomized trials, no independent replication of the 2005 findings, no standardized protocol validated by trials, and no long-term outcome data at scale.
Whether EBOO produces meaningful clinical benefit for any condition beyond the narrow 2005 finding remains scientifically unknown. Anyone who tells you otherwise is ahead of the evidence.
If you want a straight, evidence-based conversation about EBOO therapy research and what it does and does not support for your situation, that is exactly what we offer. Book a consultation, and we will give you an honest picture, or you can learn more about our EBOO therapy service.
I offer EBOO, and I am the one telling you the evidence is thin. That is deliberate. I would rather you decide with the real picture than a marketed one. The science currently supports only modest conclusions: a coherent mechanism, one small positive trial, and many open questions. I think that can still be a reasonable basis for some people to try it, with clear expectations and proper screening. It is not a basis for promising anyone a cure, and I will not do that. When larger and better research arrives, I will update what I tell patients accordingly.
Partly. EBOO research includes one small randomized controlled trial (28 patients, peripheral artery disease, 2005), an earlier uncontrolled case series, and laboratory work on the mechanism. A 2026 umbrella review found that ozone therapy did not consistently beat placebo overall. The evidence is early and limited, not conclusive.
Just one randomized controlled trial of EBOO specifically (Di Paolo et al., 2005), plus an uncontrolled case series and mechanistic laboratory studies. Claims of large meta-analyses of thousands of EBOO patients are not real.
No. The FDA classifies ozone as a toxic gas with no approved medical use, and no ozone device holds FDA approval for therapeutic use in people. EBOO is offered within the practice of medicine and paid for out of pocket.
No. No research shows EBOO cures any disease. The strongest study showed improvement in skin lesions in a small trial of patients with peripheral artery disease. That is a specific, limited finding, not proof it cures anything.
It found that across the conditions studied, ozone therapy did not consistently outperform placebo or standard care, and it rated the overall certainty of evidence as low. It excluded EBOO-specific trials because no body of evidence exists.
At Purefico Medspa and Longevity Center in Cornelius, near Charlotte, we are happy to walk you through the actual studies and their limits at a consultation, so you can decide based on real evidence rather than marketing.
1. Di Paolo N, Bocci V, Salvo DP, et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. International Journal of Artificial Organs. 2005;28(10):1039-1050.
2. Di Paolo N, Bocci V, Garosi G, et al. Extracorporeal blood oxygenation and ozonation (EBOO) in man: preliminary report. International Journal of Artificial Organs. 2000;23:131-141.
3. Bocci V, Di Paolo N. Extracorporeal blood oxygenation and ozonation (EBOO): clinical and biological implications of ozone therapy. Redox Report. 2005;10(3):121-130.
4. Galie M, et al. The role of Nrf2 in the antioxidant response to ozone. (Mechanistic support for the hormesis pathway.) 2019.
5. Cacciatore S, et al. Effectiveness and safety of ozone therapy: an umbrella review of systematic reviews and meta-analyses. Medical Sciences (Medicina). 2026;14(2):289.
Melissa Lynch, NP, is a nurse practitioner with 28 years of clinical experience and the founder of Purefico MedSpa & Therapy, with locations in Cornelius and Archdale, North Carolina.
